Search
MyCE with MyMatrixx
Continuing Education Webinars
The following presentations were previously broadcast as live webinars and recorded by MyMatrixx. They are available to view and download, however, the recordings do not qualify for CE credit.
Industry news website WorkersCompensation.com shared some key insights from Phil Walls, myMatrixx’s Chief Clinical Officer, after a recent webinar on legacy claims. The webinar, entitled “A Prescription for Settling Legacy Claims” features both Walls and Dan Anders, Esq., Chief Compliance...
On August 7, 2024, the U.S. Food and Drug Administration (FDA) approved Purdue Pharma's Zurnai® (nalmefene) autoinjector for emergency treatment of opioid overdose in individuals aged 12 years and older.
It has been a busy year for state legislatures with many bills introduced that would impact the workers’ comp industry and pharmacy benefit managers (PBMs).
myMatrixx Chief Clinical Officer, Phil Walls, will join Dan Anders, Esq., Chief Compliance Officer for Tower MSA Partners on Wednesday, May 20, 2020, from 2:00 PM to 3:00 PM EDT as panelists in a webinar discussing effective solutions for settling legacy workers’ compensation claims. It’s well...
Let's connect at the 2024 National Comp conference being held at the Mandalay Bay in Las Vegas on October 15-17!
As claims age, the percentage of spend for prescription drugs increases. Further, as claims age, the likelihood that the injured worker becomes a Medicare beneficiary as a result of age or disability increases. The result, high prescription drug costs allocated in the Medicare Set-Aside (MSA) become...
The opioid epidemic has become a national public health problem. Although, the opioid epidemic is being addressed nationally and drug overdose deaths decreased by 4% from 2017 to 2018, still more than 67,000 people died from drug overdoses in 2018, and almost 70% involved a prescription or illicit opioid....
The FDA has issued a warning against the use of hydroxychloroquine and chloroquine for COVID-19 outside a hospital or clinical trial setting due to the increased risk for heart rhythm issues. These medications have not been shown to be safe and effective for treating or preventing COVID-19. Earlier...